Challenges of developing an ADA assay for bispecific antibody therapeutics and ADA characterization

Bispecifics are biopharmaceutical products that bind to two different targets. In this application note, LGC describes the challenges of building anti-drug antibody (ADA) assays, and how to overcome these challenges. Download to explore how LGCs tiered approach provides validated assays that will support sample analysis throughout the method lifecycle.